[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336579-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336579-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","essential-gene-screening-identifies-the-bromodomain-containing-protein-brpf1-as-a-new-actionable-target-for-endocrine-therapy-resistant-breast-cancers","Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers","","Identifying master epigenetic factors controlling proliferation and survival enables discovery of molecular targets to overcome resistance to current treatments. In breast cancer, endocrine therapy resistance involves abnormal ERα signaling driven by genetic and epigenetic events that remain largely unknown. Using computational genome-wide drop-out screening with siRNA knock-down, the study identifies BRPF1 as essential in luminal-like ERα+ tumors and applies profiling, gene ablation, inhibition, and functional assays to show ERα-associated chromatin effects, reduced proliferation, and estrogen-signaling blockade.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/essential-gene-screening-identifies-the-bromodomain-containing-protein-brpf1-as-a-new-actionable-target-for-endocrine-therapy-resistant-breast-cancers/336579/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/essential-gene-screening-identifies-the-bromodomain-containing-protein-brpf1-as-a-new-actionable-target-for-endocrine-therapy-resistant-breast-cancers/336579.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in breast cancer treatment?","Question",{"text":63,"@type":64},"The study focuses on endocrine therapy resistance in breast cancer, driven by aberrant ERα signaling from genetic and epigenetic events that are not fully understood.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers identify BRPF1 as an essential gene?",{"text":68,"@type":64},"They combined computational analysis of genome-wide drop-out screenings with siRNA-mediated gene knock-down to find essential genes in luminal-like, ERα+ breast cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports BRPF1 as a potential target?",{"text":72,"@type":64},"Chromatin and transcriptome profiling, gene ablation, and targeted pharmacological inhibition show BRPF1 associates with ERα on breast cancer cell chromatin and its blockade inhibits cell-cycle progression and reduces proliferation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336579,1791085580,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Salvati etal. Molecular Cancer (2024) 23:160 Molecular Cancer  \n[https://doi.org/10.1186/s12943-024-02071-2](https://doi.org/10.1186/s12943-024-02071-2)  \nCORRESPONDENCE Open Access  \nEssential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers  \nAnnamaria Salvati 1,2†, Giorgio Giurato 1,3†, Jessica Lamberti 1, Ilaria Terenzi 1, Laura Crescenzo 1, Viola Melone 1, Luigi Palo 1,3, Alessandro Giordano 1,3, Francesco Sabbatino4, Giuseppina Roscigno5,6, Cristina Quintavalle7, Gerolama Condorel li6,7, Francesca Rizzo 1,3, RobertaTaral lo 1,3, Giovanni Nassa 1,3*† and Alessandro Weisz 1,2,3*†  \nAbstract  \nIdentifying master epigenetic factors controlling proliferation and survival of cancer cells allows to discover new molecular targets exploitable to overcome resistance to current pharmacological regimens. In breast cancer (BC), resistance to endocrine therapy (ET) arises from aberrant Estrogen Receptor alpha (ERα) signaling caused by genetic and epigenetic events still mainly unknown. Targeting key upstream components of the ERα pathway provides a way to interfere with estrogen signaling in cancer cells independently from any other downstream event. By combining computational analysis of genome-wide ‘drop-out’ screenings with siRNA-mediated gene knock-down (kd), we identified a set of essential genes in luminal-like, ERα + BC that includes BRPF1, encoding abromodomain-containing protein belonging to a family of epigenetic readers that act as chromatin remodel ers to control gene transcription. To gather mechanistic insights into the role of BRPF1 in BC and ERα signaling, we applied chromatin and transcriptome profiling, gene ablation and targeted pharmacological inhibition coupled to cellular and functional assays. Results indicate that BRPF1 associates with ERα onto BC cell chromatin and its blockade inhibits cell cycle progression, reduces cell proliferation and mediates transcriptome changes through the modulation of chromatin accessibility. This effect is elicited by a widespread inhibition of estrogen signaling, consequent to ERα gene silencing, in antiestrogen (AE) -sensitive and-resistant BC cells and pre-clinical patientderived models (PDOs) . Characterization of the functional interplay of BRPF1 with ERα reveals a new regulator of  \n\n| †Annamaria Salvati and Giorgio Giurato contributed equally to this work. |\n| --- |\n| †Giovanni Nassa and Alessandro Weisz are share last authorship. |\n\n*Correspondence: Giovanni Nassa[gnassa@unisa.it](gnassa@unisa.it)[ ](gnassa@unisa.it)Alessandro Weisz [aweisz@unisa.it](aweisz@unisa.it)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nSalvati et al. Molecular Cancer (2024) 23:160 Page 2 of 11  \nestrogen-responsive BC cell survival and suggests that this epigenetic factor is a potential new target for tr","cbCaifG8gY40E5hY","https://ap.wps.com/l/cbCaifG8gY40E5hY","pdf",6294488,11,"English","# Abstract\n## Background\n## Keywords","[{\"question\":\"What problem does the study address in breast cancer treatment?\",\"answer\":\"The study focuses on endocrine therapy resistance in breast cancer, driven by aberrant ERα signaling from genetic and epigenetic events that are not fully understood.\"},{\"question\":\"How did the researchers identify BRPF1 as an essential gene?\",\"answer\":\"They combined computational analysis of genome-wide drop-out screenings with siRNA-mediated gene knock-down to find essential genes in luminal-like, ERα+ breast cancer.\"},{\"question\":\"What experimental evidence supports BRPF1 as a potential target?\",\"answer\":\"Chromatin and transcriptome profiling, gene ablation, and targeted pharmacological inhibition show BRPF1 associates with ERα on breast cancer cell chromatin and its blockade inhibits cell-cycle progression and reduces proliferation.\"}]","Essential gene screening identifies the bromodomain-containing protein BRPF1 as a new actionable target for endocrine therapy-resistant breast cancers | PDF",1790015712,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb80c898924d5ce77fabb5917c7590f8.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30812a832fbe447644329a0ddb4c524e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9d9c85b55ce342113b5d6d081851e65.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68d76bcc69caa867e47d0fd826aa3ea3.webp",980,1306]